The management of hypertension has seen significant advancements in recent years, with new strategies revolutionizing patient care.
The American Heart Association and the American College of Cardiology released updated guidelines in 2017, lowering the threshold for hypertension diagnosis. This change emphasizes early intervention and lifestyle modifications.
Novel antihypertensive drugs, such as angiotensin receptor-neprilysin inhibitors (ARNIs), have shown promise in recent trials. ARNIs, alongside traditional medications, offer more comprehensive and personalized treatment plans.
Digital health technologies, including telemedicine and remote patient monitoring, are providing unprecedented opportunities for real-time data collection and personalized care. These tools can enhance patient adherence and improve outcomes.
These advancements are revolutionizing hypertension care, emphasizing early intervention, personalized treatment, and the utilization of digital health technologies. As our understanding of hypertension evolves, so too must our strategies for its management.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation